Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

3.29 -9.86

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.24

Max

3.71

Chiffres clés

By Trading Economics

Revenu

-19M

-25M

Ventes

-22M

2.8M

BPA

-0.26

Marge bénéficiaire

-882.444

Employés

87

EBITDA

-18M

-23M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+96.19% upside

Dividendes

By Acuity

Prochains Résultats

10 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

266M

560M

Ouverture précédente

13.15

Clôture précédente

3.29

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 342 Classement par Healthcare

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2026, 23:56 UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

9 juil. 2026, 23:51 UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

9 juil. 2026, 23:51 UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

9 juil. 2026, 23:46 UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

9 juil. 2026, 23:36 UTC

News

Starbucks is developing AI tools to save $2 billion, including $400 million in software costs. Shares are higher in after-market trading.

9 juil. 2026, 23:16 UTC

News

Micron Technology expands U.S. investment to $250 billion by 2035, boosting capital expenditures by $50 billion. Shares rise in after-market trading.

9 juil. 2026, 23:06 UTC

Social Media
News

Tesla shares declined in after-market trading following a Hold rating from Citizens' Andrew Boone, who cited caution on the company's AI timeline.

9 juil. 2026, 20:07 UTC

News

BMO Capital initiated coverage on Align Technology with an Outperform rating and a price target of $209, contributing to positive sentiment despite leadership changes.

9 juil. 2026, 20:07 UTC

Correlated Moves
News

The iShares Core U.S. Aggregate Bond ETF is advancing today, supported by a decline in Treasury yields and positive labor market data.

9 juil. 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

SPDR S&P 500 ETF Trust advances amid mixed market sentiment and geopolitical tensions. Initial jobless claims fell to 215,000, supporting positive momentum.

9 juil. 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

The iShares Russell 2000 ETF is gaining amid geopolitical tensions and positive economic indicators, despite earlier fluctuations in the session.

9 juil. 2026, 20:07 UTC

Social Media
News
Correlated Moves
Macro Event

The iShares iBoxx $ Investment Grade Corporate Bond ETF and iShares TIPS Bond ETF are trading higher, supported by falling Treasury yields and improved jobless claims.

9 juil. 2026, 20:07 UTC

News
Social Media

Alphabet Inc. shares are lower amid concerns about its AI competitiveness, as a report suggests Meta may surpass Google in frontier AI capabilities.

9 juil. 2026, 20:07 UTC

Social Media
Correlated Moves
News

Western Digital shares rise as Micron plans $250 billion investment in U.S. memory production, boosting demand and pricing in the memory chip sector.

9 juil. 2026, 20:07 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials shares advanced on analyst target increases amid strong demand outlook. The Nasdaq 100's rise also supported the stock's performance.

9 juil. 2026, 20:07 UTC

Social Media
News
Correlated Moves

Broadcom Inc gains as it joins Morningstar's "Cheap Stocks to Buy" list and announces a multiyear, $30 billion partnership with Apple for chip production.

9 juil. 2026, 20:07 UTC

Correlated Moves
Social Media
News

Citibank's CIO survey shows Microsoft leads AI funding, with 69% from new budgets. Shares are trading higher amid positive sentiment and ongoing challenges.

9 juil. 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees $70 million in ETF inflows, the largest in 28 days. Despite negative social media sentiment, the asset is trading higher since Wednesday's close.

9 juil. 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's policy review may also support investor confidence in the cryptocurrency.

9 juil. 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's review of monetary policy may also boost investor confidence.

9 juil. 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees significant inflows of $70 million from ETFs, marking the largest daily increase in 28 days, contributing to its higher trading position since Wednesday.

9 juil. 2026, 20:06 UTC

News

J B Hunt Transport Services is higher today after Goldman Sachs and Citigroup raised their price targets, reflecting positive assessments of the company's performance.

9 juil. 2026, 20:06 UTC

News

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims related to the company's financial practices.

9 juil. 2026, 20:06 UTC

Social Media
News

Shares of Alphabet Inc. are lower amid concerns over its AI competitiveness, following a report suggesting Meta may surpass Google in frontier AI capabilities.

9 juil. 2026, 20:06 UTC

Event
News
Social Media
Correlated Moves

Intuit Inc. shares rise as the company goes ex-dividend for $1.20. Investor interest grows amid overall market strength and positive sentiment in technology stocks.

9 juil. 2026, 20:06 UTC

News
Correlated Moves

Geopolitical tensions following U.S. airstrikes on Iran have increased demand for safe-haven currencies, with CHF/HKD trading slightly higher during Thursday's session.

9 juil. 2026, 20:03 UTC

News
Social Media
Event
Macro Event

PepsiCo Inc's stock is lower following mixed second-quarter earnings, with revenue at $24.18 billion but adjusted EPS of $2.20 missing estimates.

9 juil. 2026, 20:02 UTC

News

Cisco Systems is trading higher as investors respond to its focus on smart building technology, including a partnership showing significant energy efficiency gains.

9 juil. 2026, 20:02 UTC

Social Media
ETF Constituents
News

Invesco QQQ Trust trades higher, recovering above $713.75, as SpaceX's Nasdaq-100 inclusion boosts interest. Strong performances from Meta, Broadcom, and AMD support the ETF.

9 juil. 2026, 20:02 UTC

Macro Event
News
Social Media
Correlated Moves

KLA shares advance as TD Cowen raises price target to $260. Positive sentiment in the semiconductor sector supports the upward movement amid increased AI demand.

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

96.19% hausse

Prévisions sur 12 Mois

Moyen 7.2 USD  96.19%

Haut 15 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

5

Achat

1

Maintien

1

Vente

Sentiment

By Acuity

180 / 342Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat